Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Valneva SE    VLA   FR0004056851


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Valneva : Receives FDA and European Approvals to Start Clinical Testing of Lyme Disease Vaccine Candidate

share with twitter share with LinkedIn share with facebook
share via e-mail
12/09/2016 | 01:01am EDT

Valneva Receives FDA and European Approvals to Start Clinical Testing of Lyme Disease Vaccine Candidate

Investor Meeting and Live Webcast on Lyme Disease, December 12th at 12pm ET

Lyon (France), December 9, 2016 - Valneva SE ("Valneva" or "the Company"), afully integrated, commercial stage biotech company focused on developing innovative life-saving vaccines, today announced that its vaccine candidate VLA15 against Lyme disease is now progressing into clinical testing (Phase I) following the Investigational New Drug application (IND) clearance from the Food & Drug Administration (FDA) and the approval of the Clinical Trial Application (CTA) in Europe (Belgium).

Currently, there is no licensed vaccine available to protect humans against Lyme disease, a multi systemic tick-transmitted infection that can cause serious health problems and disabilities. Each year, an estimated 300,000 Americans and 85,000 Europeans develop Lyme disease and according to the CDC (Centers for Disease Control and Prevention), it is the fastest growing vector-borne infectious disease in the United States.

Valneva is developing a new hexavalent, protein subunit-based vaccine targeting the Outer Surface Protein A (OspA) of Borrelia. OspA is, one of the most dominant proteins expressed by the bacteria when present in a tick. Pre-clinical data showed that Valneva's vaccine candidate can provide protection against the majority of Borrelia species pathogenic for humans[1].

Thomas Lingelbach, President and CEO, and Franck Grimaud, Deputy CEO of Valneva, commented, "We are very pleased to be able to advance our Lyme vaccine candidate which is intended to address such an important unmet medical need. We are committed to finding ways to accelerate the clinical development path to licensure, given that we are conducting the only active vaccine program in the industry."

Valneva's Phase I trial VLA15-101 is being conducted at two sites - one in the U.S. and one in Europe (Belgium)  and will enroll 180 subjects, aged 18-40 years. The primary objective of the single-blind, partially randomized, dose escalation study will be to evaluate the product candidate's safety and tolerability. Immunogenicity, measured by observing IgG antibodies specific against six OspA serotypes, will also be monitored for different dose groups and formulations at different time-points.

Investor Meeting and Live Webcast in New York, December 12th, 12pm Eastern Time

Considering the strong interest shown on the disease by investors, shareholders and the general public, Valneva is hosting a conference on Lyme disease in New York on December 12, 2016 to provide more detailed information on the disease and the opportunity to develop a vaccine. The conference will be co-presented by Prof. Stanley A. Plotkin, Emeritus Professor, University of Pennsylvania, and Valneva's Lyme R&D experts led by CEO Thomas Lingelbach. To register for the conference, please visit Valneva's website (http://www.valneva.com/en/)

About Valneva SE

Valneva is a fully integrated, commercial stage biotech company focused on developing innovative life-saving vaccines.

The Company seeks financial returns through focused R&D investments in promising product candidates and growing financial contributions from commercial products, striving towards financial self-sustainability.

Valneva's portfolio includes two commercial vaccines for travelers: IXIARO®/JESPECT® indicated for the prevention of Japanese encephalitis and DUKORAL® indicated for the prevention of cholera and, in some countries, prevention of diarrhea caused by ETEC. The Company has proprietary vaccines in development including candidates against Clostridium difficile and Lyme Borreliosis. A variety of partnerships with leading pharmaceutical companies complement the Company's value proposition and include vaccines being developed using Valneva's innovative and validated technology platforms (EB66® vaccine production cell line, IC31® adjuvant).

Valneva is listed on Euronext-Paris and the Vienna stock exchange and has operations in France, Austria, Great Britain, Sweden, Canada and the US with over 400 employees. More information is available at www.valneva.com.



Laetitia Bachelot-Fontaine                Teresa Pinzolits

Head of Investor Relations               Communications Specialist

& Corporate Communications          T +43-1-206 20-1116 

T +02-28-07-14-19                           M +43-676-84 55 67 357

M +33 (0)6 4516 7099                     communications@valneva.com


Forward-Looking Statements

This press release contains certain forward-looking statements relating to the business of Valneva, including with respect to the progress, timing and completion of research, development and clinical trials for product candidates, the  ability to manufacture, market, commercialize and achieve market acceptance for product candidates, the ability to protect intellectual property and operate the business without infringing on the intellectual property rights of others, estimates for future performance and estimates regarding anticipated operating losses, future revenues, capital requirements and needs for additional financing. In addition, even if the actual results or development of Valneva are consistent with the forward-looking statements contained in this press release, those results or developments of Valneva may not be indicative of their in the future. In some cases, you can identify forward-looking statements by words such as "could," "should," "may," "expects," "anticipates," "believes," "intends," "estimates," "aims," "targets," or similar words. These forward-looking statements are based largely on the current expectations of Valneva as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the expectations of Valneva could be affected by, among other things, uncertainties involved in the development and manufacture of vaccines, unexpected clinical trial results, unexpected regulatory actions or delays, competition in general, currency fluctuations, the impact of the global and European credit crisis, and the ability to obtain or maintain patent or other proprietary intellectual property protection. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made during this presentation will in fact be realized. Valneva is providing the information in these materials as of this press release, and disclaim any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: VALNEVA via Globenewswire

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on VALNEVA SE
03/26VALNEVA : Reports Positive End-of-Phase 2 Chikungunya Meeting with the U.S. FDA ..
03/25Valneva Reports Positive End-of-Phase 2 Chikungunya Meeting with the U.S. FDA..
03/24Valneva Provides Business Update on COVID-19 Situation
03/09VALNEVA : Announces FDA Approval of IXIARO Shelf Life Extension to 36 Months New..
03/08Valneva Announces FDA Approval of IXIARO® Shelf Life Extension to 36 Months; ..
02/27Valneva Reports Record Product Sales and Major Pipeline Progress in 2019
02/27VALNEVA SE : Annual results
02/03Valneva Announces New $85 Million Financing Arrangement with Leading US Healt..
01/15VALNEVA : - US DoD Exercises Option on IXIARO Supply Contract Bringing Total Val..
01/14VALNEVA : US DoD Exercises Option on IXIARO® Supply Contract Bringing Total Valu..
More news
Financials (EUR)
Sales 2019 124 M
EBIT 2019 1,73 M
Net income 2019 -5,28 M
Finance 2019 48,1 M
Yield 2019 -
P/E ratio 2019 -50,5x
P/E ratio 2020 -5,17x
EV / Sales2019 1,30x
EV / Sales2020 2,01x
Capitalization 209 M
Duration : Period :
Valneva SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VALNEVA SE
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 5
Average target price 5,06  €
Last Close Price 2,30  €
Spread / Highest target 196%
Spread / Average Target 120%
Spread / Lowest Target 21,7%
EPS Revisions
Thomas Lingelbach Co-President & Chief Executive Officer
Franck Charles Marie Grimaud Co-President & Chief Business Officer
Frédéric Grimaud Chairman-Supervisory Board
David Muir Lawrence Chief Financial Officer
Wolfgang Bender Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
VALNEVA SE-10.51%229
LONZA GROUP8.10%29 660
IQVIA HOLDINGS INC.-26.88%20 658
CELLTRION, INC.3.08%20 147